What Is CendR? Definition and What Research Reports

Plain definition

CendR is short for the C-end Rule. It names a sequence pattern found in certain short peptides: a basic motif written as R/KXXR/K (arginine or lysine, two variable residues, then another arginine or lysine) that is only active when it sits at the peptide's free carboxy-terminal end. When that motif is exposed at the C-terminus, it can engage the b1 domain of neuropilin-1 (NRP-1), a cell-surface co-receptor. Reviews of tumour-penetrating peptides described this engagement as the trigger for an endocytic, tissue-penetrating transport route rather than simple surface binding (PMID 23986882). If the same residues are buried inside a longer sequence, or if the C-terminus is blocked or amidated, the rule does not apply — position is the defining feature, which is why the term is a "rule" about the end of a peptide rather than a name for a single molecule.

What class of molecule is it, and where does it come from?

CendR is not itself a compound. It is a motif — a description of a few amino acids and their location — that can appear in many different peptides and in natural protein fragments. Peptides carrying it are short synthetic sequences, typically under a dozen residues, sometimes cyclised, and they belong to the broader family of homing and tumour-penetrating peptides catalogued in reviews of peptide-guided delivery (PMID 33543454).

The motif was identified through phage-display screening work on tumour-homing peptides, and the same review literature traced it back to endogenous ligands: vascular endothelial growth factor family members and processed semaphorins end in comparable basic C-terminal sequences that bind neuropilins (PMID 23986882). Two mechanistic ideas travel with the term:

• Cryptic CendR. A peptide can be designed so the motif is hidden until a protease cleaves the sequence at the target site. Researchers building a urokinase-controlled tumour-penetrating peptide reported that proteolytic processing was used to unmask the C-terminal element and so restrict activity to tissue where that protease was present (PMID 27106816).
• Bystander transport. Reviews described the CendR pathway as capable of carrying co-administered or conjugated cargo — small molecules, antibodies, nanoparticles — rather than only the peptide itself (PMID 23986882).

How the term is used in peptide research

In papers, "CendR" usually appears in one of three ways: as a motif ("the sequence contains a CendR element"), as a pathway ("uptake proceeded through the CendR pathway"), or as an adjective for a peptide class ("a CendR-activated peptide"). Most of that usage sits in oncology drug delivery, where the interest is in moving payloads out of blood vessels and deeper into solid tissue. A second, smaller body of work uses the term in virology, because some viral surface proteins generate CendR-conforming ends after host protease cleavage.

Peptides commonly described in CendR terms

What the published literature reports

The published work on CendR peptides is preclinical and mechanistic. In oncology models, the study of iRGD reported that the tumour-penetrating peptide inhibited metastasis in experimental settings, and framed that result in terms of the peptide's tissue-penetration activity rather than direct cytotoxicity (PMID 25392370). Separately, researchers who screened for a systemically delivered peptide against the extracellular matrix protein tenascin-C reported homing to tumour tissue in mouse models with the PL3 peptide (PMID 32242067), and a 2025 nanoparticle report described hybrid lipid–polymer particles functionalised with the tumour-penetrating peptide LinTT1 evaluated for glioblastoma targeting (PMID 41098563). A medicinal-chemistry review of tLyP-1 summarised its characterisation as an NRP-1-directed sequence and the design work built around it (PMID 36332316).

The motif also shows up outside cancer biology. A 2020 report in Science concluded that neuropilin-1 acts as a host factor for SARS-CoV-2 infection, linking that role to the furin-cleaved spike S1 fragment whose new C-terminus conforms to the CendR pattern (PMID 33082294). A subsequent theoretical review of host-manipulation mechanisms discussed neuropilin engagement alongside other entry routes described for the virus (PMID 34902063). Earlier virology work had already reported a novel neuropilin-1-binding sequence within the human T-cell lymphotropic virus type 1 envelope glycoprotein (PMID 29458191). Taken together, these papers describe the motif as a shared point of contact between designed peptides and some naturally occurring protein ends — not as an established clinical intervention.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving a drug, supplement or investigational compound.

Common points of confusion

CendR is not the same as "cell-penetrating peptide"

Classic cell-penetrating peptides such as polyarginine sequences work largely through charge-driven membrane interaction. Tumour-penetrating-peptide reviews distinguished the CendR route as receptor-dependent — requiring neuropilin engagement and an exposed C-terminus — and associated it with transport through tissue layers rather than entry into a single cell (PMID 23986882).

CendR is not CaeNDR

Searches for the term sometimes surface CaeNDR, the Caenorhabditis Natural Diversity Resource, which is a genomics database for nematode strains and has no relationship to peptide motifs (PMID 37855690). The similarity is purely orthographic.

"Homing" and "penetrating" describe different steps

Reviews of homing peptides used "homing" for the accumulation step at a target tissue and reserved "penetrating" for subsequent movement into that tissue; some sequences were described as doing both, in stages (PMID 33543454).

What the literature has not established

The sources cited here are laboratory and animal studies, structural work and reviews. None of them is presented as evidence for a human therapeutic product, and the verified literature summarised on this page does not contain human dosing information, human safety outcomes or approved indications for CendR peptides. Where researchers reported effects, those effects were measured in cell culture or in rodent models, and the papers themselves frame the motif as a delivery and mechanism concept under investigation.

Related glossary terms

• Neuropilin-1 (NRP-1) — the receptor whose b1 domain pocket accepts the C-terminal basic motif, and which was reported to act as a host factor in SARS-CoV-2 infection (PMID 33082294).
• Tumour-penetrating peptide — the peptide class most often carrying the motif (PMID 23986882).
• Homing peptide — the broader targeting category (PMID 33543454).
• Cryptic / protease-activated motif — designs in which cleavage unmasks the active end (PMID 27106816).

References

• Tumor-penetrating peptides (Frontiers in Oncology, 2013)
• Homing Peptides for Cancer Therapy (Advances in Experimental Medicine and Biology, 2021)
• Urokinase-controlled tumor penetrating peptide (Journal of Controlled Release, 2016)
• Tumor-penetrating iRGD peptide inhibits metastasis (Molecular Cancer Therapeutics, 2015)
• Tumor-penetrating peptide for systemic targeting of Tenascin-C (Scientific Reports, 2020)
• tLyp-1: A peptide suitable to target NRP-1 receptor (Bioorganic Chemistry, 2023)
• LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting (ACS Pharmacology & Translational Science, 2025)
• Neuropilin-1 is a host factor for SARS-CoV-2 infection (Science, 2020)
• Host Manipulation Mechanisms of SARS-CoV-2 (Acta Biotheoretica, 2021)
• A novel neuropilin-1-binding sequence in the human T-cell lymphotropic virus type 1 envelope glycoprotein (BBA Proteins and Proteomics, 2018)
• CaeNDR, the Caenorhabditis Natural Diversity Resource (Nucleic Acids Research, 2024)